BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
Day: December 16, 2025
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFR™ System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...
Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon...
Jushi Holdings Inc. Announces Amendment to CEO Employment Agreement
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Jushi Holdings Inc. Announces Amendment to CEO Employment Agreement
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Jushi Holdings Inc. Announces Amendment to CEO Employment Agreement
BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of...
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of...
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of...
Annovis to Host Corporate Update Webinar on January 28, 2026
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical...
Annovis to Host Corporate Update Webinar on January 28, 2026
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical...